- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04436731
Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity
April 3, 2023 updated by: Jacqueline K Limberg, PhD, University of Missouri-Columbia
Patients with sleep apnea are at increased risk of developing cardiovascular disease - with women at potentially greater risk than men.
Contributing mechanisms are not well understood, but may be related to how women respond to low oxygen and, given over 70% of patients with sleep apnea are obese, the impact of obesity.
This project seeks to increase our understanding of mechanisms that may contribute to sex differences in the cardiovascular response to low oxygen with the hope that this knowledge will improve the efficacy of current therapies and support the discovery of novel therapeutics.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
104
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jennifer L Harper, B.S.
- Phone Number: 573-882-2544
- Email: harperjl@missouri.edu
Study Locations
-
-
Missouri
-
Columbia, Missouri, United States, 65211
- Recruiting
- University of Missouri-Columbia
-
Contact:
- Jacqueline K Limberg, Ph.D.
- Phone Number: 573-882-2420
- Email: limbergj@Missouri.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-45 years of age (premenopausal)
- Healthy weight (BMI ≥18 and ≤25 kg/m2)
- Obese (BMI ≥30 kg/m2)
Exclusion Criteria:
- Pregnancy, breastfeeding, oral hormonal contraceptive use
- Diagnosed sleep apnea or Oxygen desaturation index >10 events/hr
- Current smoking/Nicotine use
- Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
- Nerve/neurologic disease
- Cardiovascular, hepatic, renal, respiratory disease
- Blood pressure ≥140/90 mmHg
- Diabetes, Polycystic ovarian syndrome
- Communication barriers
- Prescription medications, Sensitivity to lidocaine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hypoxia Exposure
A physician will place a catheter in the brachial artery for intra-arterial pharmacological infusions.
The following drugs will be administered to each participant under room air (normoxic) and low oxygen (hypoxic) conditions: phenylephrine, dexmedetomidine, norepinephrine, phentolamine (see Interventions for details).
|
Systemic oxygen levels will be titrated to attain hypoxemia as assessed by pulse oximetry.
Phenylephrine (0.0625 mcg/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
Other Names:
Dexmedetomidine (12.5 ng/dL/min) will be locally infused via brachial artery catheter during the final 3 min of normoxia and hypoxia.
Phentolamine will be locally infused via brachial artery catheter for 10 min before baseline measurement (12 mcg/dL/min) and the infusion will continue at a maintenance rate (5 mcg/dL/min) during acute normoxia and hypoxia.
Other Names:
Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in forearm vascular conductance with intra-arterial drug infusion
Time Frame: Continuous measurement of vascular conductance during infusion of each drug (final 3 min of normoxia and hypoxia).
|
Vascular conductance is an index of vascular tone and is measured using a technique called venous occlusion plethysmography.
|
Continuous measurement of vascular conductance during infusion of each drug (final 3 min of normoxia and hypoxia).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 9, 2020
Primary Completion (Anticipated)
June 30, 2025
Study Completion (Anticipated)
June 30, 2025
Study Registration Dates
First Submitted
June 8, 2020
First Submitted That Met QC Criteria
June 15, 2020
First Posted (Actual)
June 18, 2020
Study Record Updates
Last Update Posted (Actual)
April 5, 2023
Last Update Submitted That Met QC Criteria
April 3, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Obesity
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Protective Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Hypnotics and Sedatives
- Respiratory System Agents
- Sympathomimetics
- Adrenergic alpha-Antagonists
- Vasoconstrictor Agents
- Mydriatics
- Nasal Decongestants
- Adrenergic alpha-1 Receptor Agonists
- Dexmedetomidine
- Norepinephrine
- Phenylephrine
- Oxymetazoline
- Phentolamine
Other Study ID Numbers
- 2022525
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Hypoxia Exposure
-
University of Castilla-La ManchaNot yet recruiting
-
University Hospital, GrenobleCompleted
-
Direction Centrale du Service de Santé des ArméesRecruitingHypoxia | Sleep DeprivationFrance
-
University of LiverpoolUniversity College London Hospitals; Oswaldo Cruz Foundation; Kamuzu University... and other collaboratorsActive, not recruitingDiseases of the Nervous System | Other Specified Viral DiseasesIndia, Brazil, Malawi
-
Pennington Biomedical Research CenterCompletedInsulin ResistanceUnited States
-
Shirley Ryan AbilityLabU.S. Department of EducationRecruiting
-
Shirley Ryan AbilityLabEdward Hines Jr. VA HospitalCompletedMultiple Sclerosis, Relapsing-RemittingUnited States
-
Indiana UniversityRehabilitation Hospital of IndianaRecruitingBrain InjuriesUnited States
-
Charite University, Berlin, GermanyCompleted